Tower Research Capital (TRC)’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Tower Research Capital (TRC)’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-709	Closed	-$32.9K	–	6442
2023 Q2	$32.9K	Sell	709 -1,093	-61%	-$37.8K	﹤0.01%	2941
2023 Q1	$52K	Buy	1,802 +1,354	+302%	+$40.1K	﹤0.01%	2466
2022 Q4	$13K	Sell	448 -790	-64%	-$25.8K	﹤0.01%	3660
2022 Q3	$25K	Sell	1,238 -373	-23%	-$6.8K	﹤0.01%	3779
2022 Q2	$25K	Sell	1,611 -253	-14%	-$4.35K	﹤0.01%	3584
2022 Q1	$36K	Buy	1,864 +1,320	+243%	+$23.6K	﹤0.01%	2995
2021 Q4	$14K	Buy	+544	New	+$15.9K	﹤0.01%	4132

Tower Research Capital (TRC)'s DICE Position: Q3 2023 in Review

Tower Research Capital (TRC) sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 709 shares — an estimated $32.9K sold.

Tower Research Capital (TRC) first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $52K in Q1 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Tower Research Capital (TRC) reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 709 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $32.9K.
Tower Research Capital (TRC) first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Tower Research Capital (TRC)'s DICE Therapeutics, Inc. Common Stock position peaked at $52K in Q1 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.